ArticleScientific reports2025
Sodium thiosulfate attenuates liver injury in a rat model of sepsis by modulating ferroptosis and oxidative stress.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Sepsis is a dysregulated immune response to infection that can present with a pro-inflammatory endotype in which the ischemia/reperfusion injury leads to excessive production of reactive oxygen species (ROS), inflammatory mediators and the activation of cell death mechanisms. Sodium thiosulfate (STS) is a hydrogen sulfide producing agent that could reduce ischemia/reperfusion injuries induced ROS, inflammation and cell death. We used the peritoneal contamination and infection model in adult rats to induce sepsis. Animals from the treatment groups received either Trolox, an antioxidant medication or STS in doses of 500mg/kg b.w. (STS500 group) or 1000mg/kg b.w. (STS1000 group). Additionally all rats received fluid resuscitation therapy, antibiotic therapy and analgesic treatment. After 48 h the rats were sacrificed and blood and liver samples collected for analysis. Both STS500 and STS1000 reduced overall the ROS production and improved antioxidant defence mechanisms. They also reduced inflammatory cytokines IL-6 and TNF-α levels. In liver samples STS reduced inflammatory alterations and ferroptosis but had little effect on pyroptosis. STS could be a potential treatment option is sepsis pro-inflammatory endotypes by improving the redox balance and inhibiting ferroptosis and inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.